CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
Delayed Nasdaq  -  05/23 04:00:00 pm EDT
25.21 USD   +1.08%
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Maintains Buy Rating
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Sell: Cerevel Therapeutics Holdings

12/28/2021 | 05:19pm EDT


© MT Newswires 2021
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
05/11Berenberg Bank Adjusts Cerevel Therapeutics Holdings Price Target to $44 From $46, Main..
MT
05/10Cerevel Therapeutics Q1 Loss Widens
MT
05/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
05/10Cerevel Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ende..
CI
05/10Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
AQ
04/18INSIDER SELL : Cerevel Therapeutics Holdings
MT
04/13Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update..
AQ
04/08SIRS 2022 PRESENTATION – EMRAC : Results From a Phase 1b Trial in Patients With Schi..
PU
04/06AAN 2022 POSTER - PHARMACOKINETICS, : Summary of Early Phase Clinical Studies
PU
04/06AAN 2022 PRESENTATION - DARIGABAT : pronounced antiepileptic activity in the mesial tempor..
PU
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -283 M - -
Net cash 2022 218 M - -
P/E ratio 2022 -12,8x
Yield 2022 -
Capitalization 3 738 M 3 738 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 228
Free-Float 81,4%
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 24,94 $
Average target price 42,86 $
Spread / Average Target 71,8%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.-23.07%3 698
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-17.77%42 735
BIONTECH SE-36.77%39 612